The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis

Author:

Butzkueven Helmut12,Hillert Jan3,Soilu-Hänninen Merja4,Ziemssen Tjalf5,Kuhle Jens67,Wergeland Stig89,Magyari Melinda10,Berger Joseph R.11,Moore Nicholas12,Aydemir Aida13,Bezemer Irene14,Sabidó Meritxell15

Affiliation:

1. Department of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia

2. The Alfred Hospital, Melbourne, VIC, Australia

3. Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden

4. Turku University Hospital Neurocenter and Division of Clinical Neurosciences, University of Turku, Turku, Finland

5. Center of Clinical Neuroscience, Department of Neurology, Dresden University of Technology, Dresden, Germany

6. Multiple Sclerosis Center and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland

7. Department of Neurology, University Hospital and University of Basel, Basel, Switzerland

8. Norwegian MS Registry and Biobank, Department of Neurology, Haukeland University Hospital, Bergen, Norway

9. Department of Clinical Medicine, University of Bergen, Bergen, Norway

10. Danish Multiple Sclerosis Center and the Danish Multiple Sclerosis Registry, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

11. Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

12. Bordeaux PharmacoEpi (BPE), Université de Bordeaux, Bordeaux, France

13. EMD Serono Research & Development Institute, Inc, Billerica, MA, USA, an affiliate of Merck KGaA

14. Global Epidemiology, IQVIA, Amsterdam, The Netherlands

15. Merck Healthcare KGaA, Darmstadt, Germany

Publisher

Informa UK Limited

Subject

General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3